Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity

J Diabetes Investig. 2024 Dec 11. doi: 10.1111/jdi.14372. Online ahead of print.

Abstract

We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.

Publication types

  • Editorial